The standard case for the fund is to invest in rounds with 2-3 partakers. Despite the Walloon, startups are often financed by Takeda Ventures, Spinventure, Jean-Pierre Delwart. The meaningful sponsors for the fund in investment in the same round are Spinventure, Meusinvest, Eurostars. In the next rounds fund is usually obtained by Rodolphe de Spoelberch, Korea Investment Partners, Inventures SA.
The fund is generally included in less than 2 deals every year. Deals in the range of 5 - 10 millions dollars are the general things for fund. The top activity for fund was in 2018.
Among the most popular portfolio startups of the fund, we may highlight Convert Pharmaceuticals, Univercells. Among the most popular fund investment industries, there are Therapeutics, Health Care. The fund has exact preference in some founders of portfolio startups. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund.
Related Funds
| Fund Name | Location |
| ACE Investment Partners Ltd. | Geneva, Geneve, Switzerland |
| Atain | Farmington Hills, Michigan, United States |
| BTM | Japan, Tokyo |
| DOCOMO Innovations | California, Palo Alto, United States |
| Elusive Ventures | Mclean, United States, Virginia |
| Foster & Foster | Florida, Fort Myers, United States |
| Glenview Capital Management | New York, New York, United States |
| Grupo Nutresa | Antioquia, Colombia, Medellín |
| GSD Capital | Las Vegas, Nevada, United States |
| Lifu Investment Management | China, Guangdong, Guangzhou |
| PaineWebber | New York, New York, United States |
| Piramal Fund Management | India, Maharashtra, Mumbai |
| SB Payment Service | Japan, Tokyo |
| SG Hiscock | - |
| SKIO Matrix | China, Hangzhou, Zhejiang |
| theDOCK Innovation Hub | - |
| Three Curve Capital | Boston, Massachusetts, United States |
| Toyota AI Ventures | California, Los Altos, United States |
| We Ventures | - |
| WIC | - |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Convert Pharmaceuticals | $16M | 28 Feb 2018 | Liège, Liège, Belgium |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Convert Pharmaceuticals | $16M | 28 Feb 2018 | Liège, Liège, Belgium |
